2-(甲基磺酰基)乙基 4-硝基苯基碳酸脂 | 53298-30-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(甲基磺酰基)乙基 4-硝基苯基碳酸脂
• 中文别名: 2-(甲基磺酰基)乙基4-硝基苯基碳酸脂；2-(甲磺酰)乙基4-硝基苯基碳酸酯
• 英文名称: 2-(methylsulfonyl) ethyl-4-nitrophenyl carbonate
• 英文别名: 4-nitrophenyl 2-(methylsulfonyl)ethyl carbonate；Tesser’s Base；2-(methylsulfonyl)ethyl 4-nitrophenyl carbonate；2-(methylsulphonyl)-ethyl-4-nitrophenylcarbonate；2-methylsulfonylethyl p-nitrophenyl carbonate；2-(Methylsulfonyl)-aethyl-p-nitrophenyl-carbonat；2-(Methylsulphonyl)ethyl 4-nitrophenyl carbonate；2-methylsulfonylethyl (4-nitrophenyl) carbonate
• CAS: 53298-30-9
• 化学式: C₁₀H₁₁NO₇S
• mdl: MFCD00014746
• 分子量: 289.266
• InChiKey: RRMVRASAASKOHS-UHFFFAOYSA-N

物化性质

• 熔点：
  100-103 °C

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  124
• 氢给体数：
  0
• 氢受体数：
  7

安全信息

• 安全说明：
  S22,S24/25
• 海关编码：
  2920909090

反应信息

• 作为反应物：
  描述：

  2-(甲基磺酰基)乙基 4-硝基苯基碳酸脂 、 1,2,5,6-tetrahydropyridine-3-carboxaldehyde-O-methyloxime hydrochloride 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以51%的产率得到Methyl ether of [1-(2-methylsulphonyl)ethoxy-carbonyl]1,2,5,6-tetrahydropyridin-3-carboxaldehyde oxime
  参考文献：
  名称：

  1-substituted-1,2,5,6-tetrahydropyridine-3-carboxaldehyde-O-alkyloximes as novel orally active and long-lasting muscarinic cholinergic agonists

  摘要：

  Our previous attempts to design muscarinic agonists related to arecoline with the prerequisites for clinical use were successful with the discovery of 1,2,5,6-tetrahydropyridine-3-carboxaldehyde-O-methyloxime hydrochloride, RU 35963, and structurally related compounds, in which die metabolically labile ester group of arecoline was replaced with the bioisosteric and stable aldoxime group. With the aim of obtaining compounds with improved cholinomimetic properties, several aryl- and alkyl-carbamates of RU 35963, as well as O-alkyl-, and O-aryl-carbamates of the 1-hydroxy-1,2,5,6-tetrahydropyridine-3- carboxaldehyde-O-methyloxime hydrochloride, 24, have been synthesized and evaluated biologically. The most interesting molecules to emerge from the primary screening have been evaluated more extensively and their cholinomimetic profiles compared with those of the parent molecules. In vitro studies indicate that none of these prodrugs have affinity for muscarinic receptor sites and some of them (aryl-carbamates) have cholinesterase inhibiting properties. Results from in vivo experiments in mice and rats showed that these new substances, 1-[4-chlorophenyl] oxycarbonyl-1,2,5,6-tetrahydropyridine-3- carboxaldehyde-O-methyloxime (16 = RU 47213) in particular, have cholinomimetic properties that compare favourably with those of the parent compounds. After oral administration 16 was clearly superior to RU 35963 in terms of central selectivity, duration of action and therapeutic indexes.

  DOI：

  10.1016/0223-5234(92)90186-5
• 作为产物：
  描述：

  2-羟乙基甲砜 、 对硝基苯基氯甲酸酯 在 吡啶 作用下， 生成 2-(甲基磺酰基)乙基 4-硝基苯基碳酸脂
  参考文献：
  名称：

  [激素-受体相互作用。借助于对碱不稳定的保护基的合成α-促黑素及其信息序列（作者的翻译）]。

  摘要：

  Hormone‐Receptor Interactions. Synthesses of α‐Melanotropin and of Informational Sequences thereof with the Aid of Alcali‐Labile Protecting Groups.The aim of this investigation was to prepare α‐melanotropin and partial sequences thereof for biological investigations in as pure a state as possible. Classical synthesis in solution was chosen as the general approach, because it allows for extensive purification and identification of all intermediates, thus warranting the chemical identity of the products (in contrast to the solidphase methods). The scheme of protection was as follows: for the Nα‐amino groups mostly t‐butoxycarbonyl (BOC‐), sometimes benzyloxycarbonyl (Z‐), for the Nϵ‐amino group of lysine‐(11) 2‐(methylsulfonyl)‐ethoxycarbonyl (MSOC‐), and for the carboxylic acid group of C‐terminal glycine‐(10) 2‐(4‐tolyl‐sulfonyl)‐ethoxy (‐OTSE). This provides for facile and mild selective deprotection of either the α‐amino groups by acidolysis or of the ϵ‐amino group (α‐carboxyl group) by β‐elimination in alcali. A slight molar excess of 0.12N HCl in HCOOH proved to be the method of choice for removing BOC‐; MSOC‐ is stable in acid (even for 30 min in liquid HF) and easily removed in a few minutes by 0.05‐‐0.1N Ba(OH)2; ‐OTSE is removed similarly. Condensation of amino‐acid and peptide derivatives (formation of the peptide link) was performed using active esters (‐ONP; ‐OSU), dicyclohexyl‐carbodiimide (DCCI) with or without 1‐hydroxy‐benzotriazole (HOBT), or carboxylic acid azides wherever histidine was the carboxylic component.More than 50 compounds are described. Those characterized by arabic numerals served to prove that α‐MSH contains two message sequences that are able to trigger melanocyte response: one in the central region ‐His‐Phe‐Arg‐Trp‐, the other in the C‐terminal portion ‐Gly‐Lys‐Pro‐Val · NH2 of the molecule [3].

  DOI：

  10.1002/hlca.19750580724
• 作为试剂：
  描述：

  2,5-二氧代吡咯-1-甲酸乙酯 、 (S)-5’-fluorenylmethyloxycarbonylamino-1’-(3”-methyl-1”,2”,4”-oxadiazoi-5”-yl)-1’-tert-butoxycarbonylaminopentane 在 2-(甲基磺酰基)乙基 4-硝基苯基碳酸脂 、 sodium hydroxide 、 碳酸氢钠 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 反应 0.25h， 以50%的产率得到(S)-5’-(N-maleimido)-1’-(3”-methyl-1”,2”,4”-oxadiazol-5”-yl)-1’-tert-butoxycarbonylaminopentane
  参考文献：
  名称：

  [EN] CARBON MONOXIDE RELEASING NORBORNENONE COMPOUNDS
  [FR] COMPOSÉS DE NORBORNÉNONE LIBÉRANT DU MONOXYDE DE CARBONE

  摘要：

  本发明提供了在生理条件或pH触发下能够释放一氧化碳的有机化合物，以及将这种化合物用于调节细胞、组织或器官，例如，在移植事件中保护免受缺血性损伤的使用方法。

  公开号：

  WO2017095237A1

文献信息

• Bicyclic heterocycles, the preparation thereof, and their use as
  申请人：Boehringer Ingelheim Pharma KG

  公开号：US06114532A1

  公开（公告）日：2000-09-05

  The present invention relates to 5-membered heterocyclic condensed benzoderivatives of formula ##STR1## wherein R.sub.a to R.sub.c, A, X and Y are defined as in claim 1, the tautomers, stereoisomers, mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable properties. The compounds of the above formula I wherein R.sub.c denotes a cyano group are valuable intermediates for preparing the other compounds of formula I, and the compounds of the above formula I wherein R.sub.c denotes one of the following amidino groups and the tautomers and stereoisomers thereof have valuable pharmacological properties, particularly an antithrombotic activity.

  本发明涉及公式##STR1##的5-成员杂环融合苯衍生物，其中R.sub.a至R.sub.c，A，X和Y的定义如权利要求1中所定义，其互变异构体，立体异构体，其混合物及其盐，特别是其与具有有价值性质的无机或有机酸或碱的生理上可接受的盐。上述公式I中R.sub.c表示氰基的化合物是制备公式I的其他化合物的有价值中间体，上述公式I中R.sub.c表示以下氨基甲酰基基团之一的化合物及其互变异构体和立体异构体具有有价值的药理学性质，特别是抗血栓活性。
• Proline derivatives
  申请人：ICI Americas Inc.

  公开号：US04596789A1

  公开（公告）日：1986-06-24

  Proline derivatives of the formulae: ##STR1## wherein R.sup.1 through R.sup.11 have defined values, and acid- and base-addition salts thereof, and equilibrium addition compounds of the aldehyde group thereof; processes for their preparation; pharmaceutical compositions; and intermediates for preparing said proline derivatives. The proline derivatives are human leukocyte elastase inhibitors which are useful, for example, in treating pulmonary emphysema.

  公式为: ##STR1## 其中R.sup.1到R.sup.11具有定义的值，以及它们的酸盐和碱盐，以及醛基的平衡加合物；其制备方法；制备所述脯氨酸衍生物的药物组合物；以及制备所述脯氨酸衍生物的中间体。这些脯氨酸衍生物是人类白细胞弹性蛋白酶抑制剂，例如在治疗肺气肿中有用。
• Melanotropin Receptors I. Synthesis and Biological Activity ofN?-(5-Bromovaleryl)-N?-deacetyl-?-melanotropin
  作者：Rudolf Wunderlin、Panagiota Minakakis、Aung Tun-Kyi、Shub Dev Sharma、Robert Schwyzer

  DOI：10.1002/hlca.19850680102

  日期：1985.2.13

  Chemical synthesis and biological activities of a new α-melanotropin derivative are described. Nα-(5-Bromovaleryl)-Nα-deacetyl-α-melanotropin contains the 5-bromopentanoyl group as a chemical ‘handle’ in place of the acetyl group of the natural hormone. The synthesis involved a new protected intermediate which allowed the selective deprotection of either the Nα or Nα amino group. The title compound

  描述了一种新的α-促黑素衍生物的化学合成和生物活性。Ñ α - （5-溴戊） - ñ α -deacetyl-α-黑激素包含5-溴戊基作为代替乙酰基的天然激素的化学“句柄”。合成涉及一种新的保护的中间体，其允许任一所述N个的选择性脱保护α或N α氨基。标题化合物用硫代硫酸钠反应，得到Ñ α -deacetyl- Ñ α-（5-（磺硫基）戊酰基）-α-促黑素，制备烟草花叶病毒/α-促黑素二硫化物结合物的关键中间体。作为研究缀合物的基础，确定了标题化合物对Cloudman S -91小鼠黑素瘤细胞培养物的生物学活性（酪氨酸酶刺激，结合和环状AMP积累）。它们被证明与相应的α-促黑素活性非常相似。结合的差异可以通过新衍生物与靶细胞膜脂质相之间更强的疏水相互作用来解释。
• Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade
  申请人：Pharmacia Corporation

  公开号：US20040082585A1

  公开（公告）日：2004-04-29

  The present invention relates to prodrug compounds, compositions and methods useful for preventing and treating thrombotic conditions in mammals. The prodrug compounds of the present invention selectively inhibit certain proteases of the coagulation cascade.

  本发明涉及一种用于预防和治疗哺乳动物血栓性疾病的前药化合物、组合物和方法。本发明的前药化合物选择性地抑制凝血级联反应中的某些蛋白酶。
• METHOD FOR SYNTHESIZING KPV TRIPEPTIDE DIAMIDE DERIVATES
  申请人：Genard Sylvie

  公开号：US20100120699A1

  公开（公告）日：2010-05-13

  The object of the invention is to provide an improved method for synthesizing a KPV tripeptide diamide derivate having the formula (I) such as defined in the specification. The synthesis method according can be implemented with any of the stereoisomers of each of the Lysine (K), Proline (P) or Valine (V) amino acid residues.

  本发明的目的是提供一种改进的方法，用于合成具有式(I)所定义的KPV三肽二酰胺衍生物。根据本合成方法，可以使用任何赖氨酸（K）、脯氨酸（P）或缬氨酸（V）氨基酸残基的立体异构体来实现。